Guerbet is a human-scale company that aims to become a new global leader in medical imaging. Pioneer in contrast media with 90 years' experience, Guerbet is the only pharmaceutical group dedicated to medical imaging worldwide, with a presence in almost 80 countries via a network of subsidiaries and distributors. The company offers a comprehensive range of CT scan, Cath Lab, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve patients' diagnosis, prognosis and quality of life. Advancing in innovation solutions, the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system) and interventional radiology while reconciling efficacy and cost containment, are at the heart of Guerbet's mission.

Type
Public
HQ
Villepinte, FR
Founded
1926
Size (employees)
2,679 (est)+7%
Guerbet was founded in 1926 and is headquartered in Villepinte, FR
Report incorrect company information

Guerbet Office Locations

Guerbet has an office in Villepinte
Show all (1)
Report incorrect company information

Guerbet Financials and Metrics

Guerbet Financials

Guerbet's revenue was reported to be €490.29 m in FY, 2015 which is a 19.7% increase from the previous period.
EUR

Revenue (FY, 2015)

490.3 m

Revenue growth (FY, 2014 - FY, 2015), %

19.7%

Gross profit (FY, 2015)

386.8 m

Gross profit margin (FY, 2015), %

78.9%

Net income (FY, 2015)

39.9 m

EBITDA (FY, 2015)

84.4 m

EBIT (FY, 2015)

56.1 m

Market capitalization (31-Oct-2017)

967 m

Closing share price (31-Oct-2017)

77.3

Cash (31-Dec-2015)

54.4 m

EV

1.3 b
Guerbet's current market capitalization is €967 m.
EURFY, 2014FY, 2015

Revenue

409.7 m490.3 m

Revenue growth, %

20%

Cost of goods sold

90.4 m103.5 m

Gross profit

319.3 m386.8 m
eurY, 2014Y, 2015

Cash

20.4 m54.4 m

Total Assets

475.6 m898.8 m

Total Debt

81.2 m342.2 m

Total Liabilities

216.5 m615 m
EURFY, 2014FY, 2015

Cash From Operating Activities

60 m74.3 m
EURY, 2015

EV/EBITDA

14.9 x

EV/EBIT

22.4 x

EV/CFO

16.9 x
Show all financial metrics
Report incorrect company information

Guerbet News and Updates

Global Guerbet Alcohols Market Expected to Success US$ 1316.7 Mn by the end of 2024

Global Market Study on Guerbet Alcohols: 2-octyldodecanol Product Type Segment Projected to Account for Significant Market Share Between 2016 and 2024 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information